Open Access

ARTICLE

STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma

Kazuhiro Yamamoto^*, Takeshi Ioroi^*, Kazuaki Shinomiya^†, Ayaka Yoshida^*, Kenichi Harada^‡, Masato Fujisawa^‡, Tomohiro Omura^*, Yasuaki Ikemi^§, Shunsaku Nakagawa^§, Atsushi Yonezawa^§, Osamu Ogawa^¶, Kazuo Matsubara^§, Takuya Iwamoto^#, Kohei Nishikawa^**, Sayaka Hayashi^††, Daichi Tohara^††, Yoji Murakami^‡‡, Takanobu Motoshima^‡‡, Hirofumi Jono^††, Ikuko Yano^*§

* Department of Pharmacy, Kobe University Hospital, Kobe, Japan
† Department of Pharmaceutical Care and Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima, Japan
‡ Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
§ Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
¶ Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
# Department of Pharmacy, Mie University Hospital, Mie, Japan
** Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan
†† Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Japan
‡‡ Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan